Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event
Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event
NEWARK, CA / ACCESSWIRE / May 7, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and investor meetings at the Citizens JMP Life Sciences Conference being held in New York City on May 13-14, 2024. Also, Dr. Patel will join a panel at the Capital One 1st Annual Biotech/Biopharma Disruptors Event being held in New York City on May 14, 2024.
加利福尼亞州紐瓦克/ACCESSWIRE/2024年5月7日/Protagonist Therapeutics, Inc.（“主角” 或 “公司”）（納斯達克股票代碼：PTGX）今天宣佈，總裁兼首席執行官迪內什·帕特爾博士將參加2024年5月13日至14日在紐約市舉行的Citizens JMP生命科學會議的爐邊談話和投資者會議。此外，帕特爾博士還將參加2024年5月14日在紐約市舉行的Capital One第一屆年度生物技術/生物製藥顛覆者活動的小組討論。
Citizens JMP Life Sciences Conference - May 13-14, 2024
Citizens JMP 生命科學會議-2024 年 5 月 13-14 日
Format: Fireside Chat
Day/Time: Monday, May 13 at 2:00-2:25 P.M. EDT
Location: New York Hilton Midtown, 1335 Avenue of the Americas, New York
Webcast: Link HERE
格式：爐邊聊天
日期/時間：美國東部時間 5 月 13 日星期一下午 2:00-2:25
地點：紐約美洲大道 1335 號紐約中城希爾頓酒店
網絡直播：此處鏈接
If you are interested in meeting with the Protagonist team during the conference, please reach out to your Citizens JMP representative. A replay of the fireside chat will be available for 90 days and published to the Events & Presentations section of the Protagonist corporate website:
如果您有興趣在會議期間與主角團隊會面，請聯繫您的Citizens JMP代表。爐邊談話的重播將持續90天，併發布到Protagonist公司網站的 “活動與演示” 部分：
Capital One 1st Annual Biotech/Biopharma Disruptors Event - May 14, 2024
Capital One 第一屆年度生物技術/生物製藥顛覆者活動——2024 年 5 月 14 日
Panel: New Potential Dermatology Treatments for Psoriasis, Urticaria, & Alopecia
Day/Time: Tuesday, May 14 at 2:45-3:45 P.M. EDT
Location: New York City
小組討論：銀屑病、蕁麻疹和脫髮的新型潛在皮膚科治療方法
日期/時間：美國東部時間 5 月 14 日星期二下午 2:45-3:45
地點：紐約市
About Protagonist
關於主角
Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities (NCEs) rusfertide and JNJ-2113 (formerly PN-235) in advanced Phase 3 stages of clinical development, both derived from the Company's proprietary technology platform. Protagonist and JNJ scientists jointly discovered PN-235 (now known as JNJ-2113) as part of Protagonist's Interleukin-23 receptor (IL-23R) collaboration with JNJ and followed it through IND-enabling pre-clinical and Phase 1 studies, with JNJ assuming responsibility for further clinical development. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate currently in a global Phase 3 development program. The randomized portion of the Phase 2 REVIVE study has been successfully completed, and results were published in The New England Journal of Medicine in February 2024. The open-label extension component of Phase 2 is ongoing, as is the global Phase 3 VERIFY study of rusfertide in polycythemia vera. Rusfertide is being co-developed and co-commercialized with Takeda pursuant to a worldwide collaboration and license agreement with Takeda announced in January 2024.
Protagonist Therapeutics是一家生物製藥公司，其基於肽的新化學實體（NCE）rusfertide和 JNJ-2113（前身爲 PN-235）處於臨床開發的後期3期階段，均源自該公司的專有技術平台。作爲Protagonis與JNJ合作的一部分，Protagonis和JNJ的科學家共同發現了 PN-235（現稱爲 JNJ-2113），這是Protagonis與JNJ合作的一部分，並隨後進行了支持IND的臨床前和1期研究，JNJ負責進一步的臨床開發。IL-23RRusfertide是天然激素hepcidin的仿製品，是該公司目前處於全球第三階段開發計劃中的主要候選藥物。2期REVIVE研究的隨機部分已成功完成，結果發表於 這個 新英格蘭醫學雜誌 2024 年 2 月。第二階段的開放標籤擴展部分正在進行中，對真性紅細胞增多症中rusfertide的全球3期VERIFY研究也在進行中。根據2024年1月宣佈的與武田簽訂的全球合作和許可協議，正在與武田共同開發Rusfertide並共同商業化。
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at .
有關Proganist、其在研候選藥物和臨床研究的更多信息，請訪問該公司的網站，網址爲。
Investor Relations Contact
投資者關係聯繫人
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
科裏·戴維斯博士
生命科學顧問
+1 212 915 2577
cdavis@lifesciadvisors.com
Media Contact
媒體聯繫人
Virginia Amann, Founder/CEO
ENTENTE Network of Companies
+1 833 500 0061
virginiaamann@ententeinc.com
弗吉尼亞·阿曼，創始人/首席執行官
ENTENTE 公司網絡
+1 833 500 0061
virginiaamann@ententeinc.com
SOURCE: Protagonist Therapeutics, Inc.
來源：Proganist Therapeutics, Inc.
譯文內容由第三人軟體翻譯。